And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is on the busy side, actually. We plan to attend another installment in our Let’s-see-them-before-they-die concert series, hang with assorted short people, and catch up on some reading. A few naps will be sprinkled about, as well. And what about you? Spring is supposedly here, so you might want to return your shovel to the shed and enjoy the great outdoors. You could take in a moving picture, spend time with someone special, or with the musical chairs being played in Washington, perhaps this is a good time to fortify your bunker. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

GlaxoSmithKline (GSK) withdrew from the bidding for the Pfizer (PFE) consumer health care business. In a brief statement, Glaxo chief executive Emma Walmsley says that, “while we will continue to review opportunities that may accelerate our strategy, they must meet our criteria for returns and not compromise our priorities for capital allocation.” For its part, Pfizer plans to continue evaluating options for the business, which was expected to fetch up to $20 billion. Glaxo was seen as the front-runner and it is not immediately clear whether there were other offers.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy